The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
Octreotide is a widely used synthetic somatostatin analogue that significantly improves the management of neuroendocrine tumours (NETs). Octreotide acts through somatostatin receptors (SSTRs). However, the molecular mechanisms leading to successful disease control or symptom management, especially w...
Guardado en:
Autores principales: | Su-Chen Li, Cécile Martijn, Tao Cui, Ahmed Essaghir, Raúl M Luque, Jean-Baptiste Demoulin, Justo P Castaño, Kjell Öberg, Valeria Giandomenico |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9793950de5904fd884b299674b0de96d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Identification of candidate serum proteins for classifying well-differentiated small intestinal neuroendocrine tumors.
por: Spyros Darmanis, et al.
Publicado: (2013) -
Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
por: Yau H, et al.
Publicado: (2017) -
Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo
por: Liu T, et al.
Publicado: (2016) -
Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by 68Ga-DOTATOC PET/CT
por: Ulrika Jahn, et al.
Publicado: (2021) -
Octreotide-Resistant Acromegaly: Challenges and Solutions
por: Corica G, et al.
Publicado: (2020)